Alpha Tau Reports 100% Local Disease Control and Favorable Safety in Pancreatic Cancer Trials at DDW 2026

summarizeSummary

Alpha Tau Medical announced highly positive updated pooled results from two first-in-human pancreatic cancer trials, showing 100% local disease control and a favorable safety profile for its Alpha DaRT therapy, presented at DDW 2026.

check_boxKey Events

• Positive Clinical Trial Results

  Updated pooled data from two first-in-human trials of Alpha DaRT in pancreatic cancer showed a 100% local disease control rate in 19 evaluable patients, with 79% achieving stable disease and 21% partial response.

• Favorable Safety Profile

  Only 8 device-associated adverse events were observed in 7 of 26 subjects (27%), with nearly all resolving within two weeks, demonstrating a strong safety profile for the treatment in heavily pre-treated patients.

• Presentation at Premier Conference

  The results were presented at Digestive Disease Week (DDW) 2026, a premier international gastroenterology conference, marking the first time Alpha DaRT clinical results were selected for oral presentation at such an event.

auto_awesomeAnalysis

This filing provides significant positive clinical data for Alpha Tau's Alpha DaRT therapy in pancreatic cancer, a notoriously difficult-to-treat indication. The achievement of 100% local disease control in evaluable patients, coupled with a favorable safety profile, represents a major de-risking event for the technology and strengthens its commercial potential. The presentation at a premier international gastroenterology conference (DDW 2026) further enhances the credibility and visibility of these results, potentially attracting investor interest and paving the way for further clinical development and regulatory approvals.